Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients With 1- 4 Brain Metastases From Solid Malignancies

Trial Profile

Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients With 1- 4 Brain Metastases From Solid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Cancer metastases; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Feb 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2017.
    • 18 Aug 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
    • 28 Aug 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top